Full-Time
Posted on 9/18/2025
Provides value-based cancer care in community
$18 - $21/hr
Plantation, FL, USA
In Person
What TOI does: The Oncology Institute of Hope and Innovation operates one of the largest community oncology practices in the United States, offering medical oncology, radiation oncology, and patient support services in a community setting rather than a hospital. How its product works: It uses a value-based care model that focuses on achieving good patient outcomes while managing costs. The institute coordinates oncology services through expert doctors and support teams to provide comprehensive, accessible cancer care, and it has demonstrated savings for Medicare. Who it’s different from: It combines a large, community-based footprint with a clear focus on value and outcomes, delivering coordinated cancer care outside hospital walls unlike many traditional fee-for-service models. What its goal is: to provide compassionate, high-quality cancer care in the community, improving outcomes for patients while controlling costs for individuals and payers.
Company Size
201-500
Company Stage
IPO
Headquarters
Cerritos, California
Founded
2007
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Hybrid Work Options
The Oncology Institute has appointed Minh Merchant as Chief Legal Officer. She will oversee legal, regulatory, compliance and privacy functions as the value-based oncology group continues to scale. Merchant brings over 20 years of experience advising public and private healthcare organisations. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women's Health and McKesson, and holds a JD from UCLA School of Law. Founded in 2007, The Oncology Institute operates over 100 clinics across five US states, serving approximately 1.9 million patients. The company employs over 180 clinicians and provides cancer care including clinical trials and transfusions in community settings.
The Oncology Institute reported its first profitable quarter on an adjusted EBITDA basis, with Q4 revenue rising 41.6% year-over-year to $142 million. Full-year 2025 revenue exceeded $500 million, up approximately 28%, with adjusted EBITDA of $147,000. Delegated capitation arrangements are driving growth. The Elevance Florida partnership, covering roughly 70,000 lives, is expected to more than double in 2026. Delegated members represent less than 5% of capitated lives but account for approximately one-third of run-rate capitated revenue. The company added around 22,000 Humana Medicare Advantage lives in Q4. Management reaffirmed 2026 guidance of $630–650 million revenue and $0–9 million adjusted EBITDA. The company ended 2025 with $33.6 million cash after reducing convertible preferred debt by $24 million.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has appointed Kristin England as its new Chief Administrative Officer (CAO), effective July 7, 2025.
The Oncology Institute to participate at the B. Riley securities 25th Annual Institutional Investor Conference.
CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) - The Oncology Institute, Inc. (NASDAQ: TOI)("TOI"), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*.